Since the close of the initial CCP drive, the Armed Services Blood Program (ASBP) has transitioned to a plan to ensure adequate supplies of CCP for future DOD beneficiaries.
“The ASBP recruiters and blood donor centers continue to use the tools and processes developed for the recruitment of potential donors to support the sustainment of the Department of Defense CCP inventory,” Taylor said, adding that “the designated inventory levels sustain the Military Health System, including the combatant commands.”
Unfortunately, CCP has a one-year shelf life, so collected units will begin to expire in 2021.
Therefore, there is no end date for collection, Taylor noted. A new CCP collection challenge comes with the new COVID-19 vaccines, which, when approved by FDA and distributed for vaccination, will “have an impact on the availability of potential donors as the vaccines come with a deferral period,” she explained.
At a Nov. 16 ceremony honoring the success of the CCP drive, Army Lt. Gen. (Dr.) Ronald Place, director of the Defense Health Agency, said: “In my opinion, that’s the best kind of outcome for our health system.”
The reforms to military medicine remain inspired by the belief that a well-integrated organization across functions, across military departments, and unified in its strategic execution, both internally and with our partners in civilian medicine, strengthens the health and readiness of our force, he explained.
To donate convalescent plasma, donors must meet basic donation requirements. Donations can be done through whole blood or apheresis, a form of plasma collection.
To qualify for the program, participants must:
- Have evidence of COVID-19 documented by two FDA-approved serological tests for SARS-CoV-2 antibodies after recovery, if prior diagnostic testing was not performed at the time COVID-19 was suspected.
- Have a complete resolution of symptoms at least 14 days before donation.
- Undergo potential additional testing if ever pregnant to determine if HLA antibodies have developed.
The DOD’s primary goals against the pandemic are to protect its people, maintain readiness and support the national COVID-19 response. In addition to aiding in the development of new therapeutic treatments for COVID-19-positive patients in DOD facilities, CCP contributes to the overall efforts to combat the disease, thus helping accomplish each of those goals.